WallStreetZenWallStreetZen

NYSE: BIO
Bio Rad Laboratories Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for BIO

Based on 3 analysts offering 12 month price targets for Bio Rad Laboratories Inc.
Min Forecast
$524.00+43.79%
Avg Forecast
$524.67+43.97%
Max Forecast
$525.00+44.06%

Should I buy or sell BIO stock?

Based on 3 analysts offering ratings for Bio Rad Laboratories Inc.
Strong Buy
Strong Buy
2 analysts 66.67%
Buy
1 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their BIO stock forecasts and price targets.

BIO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Wells Fargo
Top 11%
90
Strong BuyMaintains$525.00+44.06%2023-08-07
RBC Capital
Bottom 5%
5
BuyMaintains$524.00+43.79%2023-08-04
Citigroup
Top 9%
92
Strong BuyMaintains$525.00+44.06%2023-05-08

1 of 1

Forecast return on equity

Is BIO forecast to generate an efficient return?
Company
6.15%
Industry
18.64%
Market
48.79%
BIO's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is BIO forecast to generate an efficient return on assets?
Company
4.34%
Industry
9.69%
BIO is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BIO revenue growth forecast

How is BIO forecast to perform vs Medical Devices companies and vs the US market?
Company
10.64%
Industry
13.29%
Market
12.08%
BIO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
BIO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

BIO vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
BIO$364.42$524.67+43.97%Strong Buy
PEN$262.43$350.22+33.45%Strong Buy
SNN$25.80N/AN/A
PODD$164.74$286.21+73.74%Buy
BRKR$64.16$82.50+28.58%Hold
View Top Medical Device Stocks

Bio Rad Laboratories Stock Forecast FAQ

Is Bio Rad Laboratories Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NYSE: BIO) stock is to Strong Buy BIO stock.

Out of 3 analysts, 2 (66.67%) are recommending BIO as a Strong Buy, 1 (33.33%) are recommending BIO as a Buy, 0 (0%) are recommending BIO as a Hold, 0 (0%) are recommending BIO as a Sell, and 0 (0%) are recommending BIO as a Strong Sell.

If you're new to stock investing, here's how to buy Bio Rad Laboratories stock.

What is BIO's forecast return on equity (ROE) for 2023-2024?

(NYSE: BIO) forecast ROE is 6.15%, which is considered weak.

What is BIO's Price Target?

According to 3 Wall Street analysts that have issued a 1 year BIO price target, the average BIO price target is $524.67, with the highest BIO stock price forecast at $525.00 and the lowest BIO stock price forecast at $524.00.

On average, Wall Street analysts predict that Bio Rad Laboratories's share price could reach $524.67 by Aug 7, 2024. The average Bio Rad Laboratories stock price prediction forecasts a potential upside of 43.97% from the current BIO share price of $364.42.

What is BIO's forecast return on assets (ROA) for 2023-2024?

(NYSE: BIO) forecast ROA is 4.34%, which is lower than the forecast US Medical Devices industry average of 9.69%.
©2023 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.